Close Menu

NEW YORK (GenomeWeb) – Twist Bioscience has filed with the US Securities and Exchange Commission for a proposed public offering of 3 million shares of its common stock, the firm said after the close of the market on Monday.

In addition, it will grant the underwriters a 30-day option to purchase an additional 450,000 shares of common stock at the public offering price. Twist has not yet priced the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.